Jahlisa S Hooiveld-Noeken, Pim P van de Donk, Laura Kist de Ruijter, Iris C Kok, Claudia A J van Winkel, Danique Giesen, Marjolijn N Lub-de Hooge, Adrienne H Brouwers, Sjoukje F Oosting, Frederike Bensch, Lotte M Smit, Carolien P Schröder, Mathilde Jalving, Sjoerd G Elias, Jourik A Gietema, Regula J Deurloo, Simon P Williams, Alexander Ungewickell, Derk-Jan A de Groot, Elisabeth G E de Vries
{"title":"Programmed death ligand 1 (PD-L1) PET/CT imaging to evaluate tumour saturation during atezolizumab treatment.","authors":"Jahlisa S Hooiveld-Noeken, Pim P van de Donk, Laura Kist de Ruijter, Iris C Kok, Claudia A J van Winkel, Danique Giesen, Marjolijn N Lub-de Hooge, Adrienne H Brouwers, Sjoukje F Oosting, Frederike Bensch, Lotte M Smit, Carolien P Schröder, Mathilde Jalving, Sjoerd G Elias, Jourik A Gietema, Regula J Deurloo, Simon P Williams, Alexander Ungewickell, Derk-Jan A de Groot, Elisabeth G E de Vries","doi":"10.1038/s41416-026-03595-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Little is known regarding tumour target saturation by the programmed death-ligand (PD-L1) antibody atezolizumab. Therefore, tumour saturation by the PD-L1 antibody atezolizumab in patients with advanced solid tumours was assessed using <sup>89</sup>Zr-atezolizumab PET imaging.</p><p><strong>Methods: </strong>Patients received 10 mg <sup>89</sup>Zr-atezolizumab after the initial 2 cycles of 1200 mg atezolizumab, followed by PET/CT scans. Tracer uptake was calculated as tumour standardized uptake value (SUV)<sub>max</sub>, normal tissues SUV<sub>mean</sub>, and tumour-to-background ratio SUV<sub>max</sub>/SUV<sub>max</sub> tumour. Tumour biopsies were obtained around day 7 of both cycles for autoradiography and PD-L1 immunohistochemistry. Findings were compared with previously reported pretreatment <sup>89</sup>Zr-atezolizumab PET/CT data.</p><p><strong>Results: </strong>Geometric mean tumour SUV<sub>max</sub> day 7 was similar between cycle 1 (5.5, 95% CI, 4.4-6.9) and 2 (5.4, 95% CI, 4.3-6.8, N = 13, P = 0.88). Geometric mean tumour-to-background ratio was 1.67 (95% CI, 1.15-2.41) and 1.53 (N = 11, 95% CI, 1.05-2.21, P = 0.32), respectively. Higher tumour-to-background ratios showed a positive trend with best overall response p<sub>trend</sub> 0.069. Autoradiography signal was present in tumour biopsies. On-treatment uptake was lower in the lesions and spleen, with a higher blood pool SUV<sub>mean</sub> than pre-treatment.</p><p><strong>Conclusions: </strong>Compared to earlier reported pre-treatment <sup>89</sup>Zr-atezolizumab PET/CT results, <sup>89</sup>Zr-atezolizumab tumour uptake during treatment is lower, suggesting partial PD-L1 tumour saturation during atezolizumab treatment.</p><p><strong>Clinicaltrials: </strong>GOV: NCT02453984, NCT02478099.</p>","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":7.8000,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41416-026-03595-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Little is known regarding tumour target saturation by the programmed death-ligand (PD-L1) antibody atezolizumab. Therefore, tumour saturation by the PD-L1 antibody atezolizumab in patients with advanced solid tumours was assessed using 89Zr-atezolizumab PET imaging.
Methods: Patients received 10 mg 89Zr-atezolizumab after the initial 2 cycles of 1200 mg atezolizumab, followed by PET/CT scans. Tracer uptake was calculated as tumour standardized uptake value (SUV)max, normal tissues SUVmean, and tumour-to-background ratio SUVmax/SUVmax tumour. Tumour biopsies were obtained around day 7 of both cycles for autoradiography and PD-L1 immunohistochemistry. Findings were compared with previously reported pretreatment 89Zr-atezolizumab PET/CT data.
Results: Geometric mean tumour SUVmax day 7 was similar between cycle 1 (5.5, 95% CI, 4.4-6.9) and 2 (5.4, 95% CI, 4.3-6.8, N = 13, P = 0.88). Geometric mean tumour-to-background ratio was 1.67 (95% CI, 1.15-2.41) and 1.53 (N = 11, 95% CI, 1.05-2.21, P = 0.32), respectively. Higher tumour-to-background ratios showed a positive trend with best overall response ptrend 0.069. Autoradiography signal was present in tumour biopsies. On-treatment uptake was lower in the lesions and spleen, with a higher blood pool SUVmean than pre-treatment.
Conclusions: Compared to earlier reported pre-treatment 89Zr-atezolizumab PET/CT results, 89Zr-atezolizumab tumour uptake during treatment is lower, suggesting partial PD-L1 tumour saturation during atezolizumab treatment.
期刊介绍：
The British Journal of Cancer is one of the most-cited general cancer journals, publishing significant advances in translational and clinical cancer research.It also publishes high-quality reviews and thought-provoking comment on all aspects of cancer prevention,diagnosis and treatment.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
